LigaChem Biosciences Inc

LigaChem Biosciences Inc has a strong liquidity position, with a current ratio of 8.54, indicating that the company holds significantly more current assets than current liabilities. The company maintains a low debt-to-equity ratio of 0.01, suggesting minimal reliance on debt financing and a strong equity base. However, the company's operating cash flow is negative at -124,532,936,680 KRW, and free cash flow is also negative at -90,984,133,620 KRW, indicating ongoing cash outflows from operations. Profitability metrics show that the company is currently unprofitable, with a return on equity of -14.63% and a return on assets of -10.58%. These figures are below the typical thresholds for profitability in the biotechnology and medical research industry, where companies often operate at a loss during early development or R&D phases. The company's operating income is negative at -106,530,862,120 KRW, and net income is also negative at -74,277,654,740 KRW, reflecting ongoing operational challenges. The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. Geographically, the company's exposure is not disclosed in the financial snapshot, but the lack of segmental or geographic diversification may pose a concentration risk. The company's total revenue for the period is 141,553,069,340 KRW, with a gross profit of 125,995,662,560 KRW, indicating a high gross margin of approximately 89%. Looking ahead, the company's growth trajectory is uncertain, as no specific revenue growth rates or outlooks are provided in the available data. Analysts have assigned a mean price target of 197,500 KRW and a median price target of 205,000 KRW, with a mean recommendation of 1.78, which is slightly above a "strong buy" rating. However, the company's negative operating and free cash flows suggest that it may require additional capital to sustain operations, which could impact future growth. The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative operating cash flow and free cash flow may necessitate future financing activities, which could lead to dilution. The company has a low dilution risk rating, but the potential for dilution remains a concern given the negative cash flows and the need for capital. Recent events and filings do not indicate any major changes in the company's operations or financial position. The company's capital expenditure for the period is -6,040,923,510 KRW, suggesting that it is not investing heavily in new assets. The company's long-term debt is relatively low at 2,749,425,870 KRW, and its cash and equivalents are 24,182,650,020 KRW, providing a buffer for short-term obligations.